MEI Pharma reports Q2 EPS 8c, consensus (14c)

Reports Q2 revenue $32.7M, consensus $6.1M. "MEI anticipates reporting key clinical data readouts on two clinical-stage oncology candidates, voruciclib and ME-344, around the end of the calendar year for each program," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "These clinical data will inform future plans in two promising areas of oncology drug development: CDK9 inhibition and mitochondrial inhibition, respectively. With approximately $124 million at the end of the quarter, we remain well capitalized to pursue these objectives and estimate that we will be able to fund operations for two years based upon our current development plans."